These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

245 related articles for article (PubMed ID: 16545157)

  • 1. Roux-en-Y gastric bypass improves the nonalcoholic steatohepatitis (NASH) of morbid obesity.
    de Almeida SR; Rocha PR; Sanches MD; Leite VH; da Silva RA; Diniz MT; Diniz Mde F; Rocha AL
    Obes Surg; 2006 Mar; 16(3):270-8. PubMed ID: 16545157
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Surgical treatment of non-alcoholic steatohepatitis and non-alcoholic fatty liver disease.
    Weiner RA
    Dig Dis; 2010; 28(1):274-9. PubMed ID: 20460923
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Roux-en-Y gastric bypass improves liver histology in patients with non-alcoholic fatty liver disease.
    Clark JM; Alkhuraishi AR; Solga SF; Alli P; Diehl AM; Magnuson TH
    Obes Res; 2005 Jul; 13(7):1180-6. PubMed ID: 16076987
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of bariatric surgery on nonalcoholic fatty liver disease: preliminary findings after 2 years.
    Furuya CK; de Oliveira CP; de Mello ES; Faintuch J; Raskovski A; Matsuda M; Vezozzo DC; Halpern A; Garrido AB; Alves VA; Carrilho FJ
    J Gastroenterol Hepatol; 2007 Apr; 22(4):510-4. PubMed ID: 17376042
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Histopathologic variability between the right and left lobes of the liver in morbidly obese patients undergoing Roux-en-Y bypass.
    Larson SP; Bowers SP; Palekar NA; Ward JA; Pulcini JP; Harrison SA
    Clin Gastroenterol Hepatol; 2007 Nov; 5(11):1329-32. PubMed ID: 17702661
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Non-alcoholic steatohepatitis: effect of Roux-en-Y gastric bypass surgery.
    Barker KB; Palekar NA; Bowers SP; Goldberg JE; Pulcini JP; Harrison SA
    Am J Gastroenterol; 2006 Feb; 101(2):368-73. PubMed ID: 16454845
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Predictors of nonalcoholic steatohepatitis in patients undergoing bariatric surgery: when is liver biopsy indicated?
    Helling TS; Helzberg JH; Nachnani JS; Gurram K
    Surg Obes Relat Dis; 2008; 4(5):612-7. PubMed ID: 18226970
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Hepatic histopathology of morbid obesity: concurrence of other forms of chronic liver disease.
    Liew PL; Lee WJ; Lee YC; Wang HH; Wang W; Lin YC
    Obes Surg; 2006 Dec; 16(12):1584-93. PubMed ID: 17217634
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The importance of routine liver biopsy in diagnosing nonalcoholic steatohepatitis in bariatric patients.
    Shalhub S; Parsee A; Gallagher SF; Haines KL; Willkomm C; Brantley SG; Pinkas H; Saff-Koche L; Murr MM
    Obes Surg; 2004 Jan; 14(1):54-9. PubMed ID: 14980034
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Predictors of nonalcoholic steatohepatitis (NASH) in obese patients undergoing gastric bypass.
    Boza C; Riquelme A; Ibañez L; Duarte I; Norero E; Viviani P; Soza A; Fernandez JI; Raddatz A; Guzman S; Arrese M
    Obes Surg; 2005 Sep; 15(8):1148-53. PubMed ID: 16197788
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Portal fibrosis and hepatic steatosis in morbidly obese subjects: A spectrum of nonalcoholic fatty liver disease.
    Abrams GA; Kunde SS; Lazenby AJ; Clements RH
    Hepatology; 2004 Aug; 40(2):475-83. PubMed ID: 15368453
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Predictors of nonalcoholic steatohepatitis and advanced fibrosis in morbidly obese patients.
    Ong JP; Elariny H; Collantes R; Younoszai A; Chandhoke V; Reines HD; Goodman Z; Younossi ZM
    Obes Surg; 2005 Mar; 15(3):310-5. PubMed ID: 15826462
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prevalence and predictors of asymptomatic liver disease in patients undergoing gastric bypass surgery.
    Beymer C; Kowdley KV; Larson A; Edmonson P; Dellinger EP; Flum DR
    Arch Surg; 2003 Nov; 138(11):1240-4. PubMed ID: 14609874
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Liver pathology in morbidly obese patients undergoing Roux-en-Y gastric bypass surgery.
    Gholam PM; Kotler DP; Flancbaum LJ
    Obes Surg; 2002 Feb; 12(1):49-51. PubMed ID: 11868297
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Hepatic histopathology of patients with morbid obesity submitted to gastric bypass.
    Lima ML; Mourão SC; Diniz MT; Leite VH
    Obes Surg; 2005 May; 15(5):661-9. PubMed ID: 15946458
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prevalence of non-alcoholic steatohepatitis in morbidly obese subjects undergoing gastric bypass.
    Spaulding L; Trainer T; Janiec D
    Obes Surg; 2003 Jun; 13(3):347-9. PubMed ID: 12841891
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Changes in liver histology accompanying massive weight loss after gastroplasty for morbid obesity.
    Stratopoulos C; Papakonstantinou A; Terzis I; Spiliadi C; Dimitriades G; Komesidou V; Kitsanta P; Argyrakos T; Hadjiyannakis E
    Obes Surg; 2005 Sep; 15(8):1154-60. PubMed ID: 16197789
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Duodenal switch has no detrimental effects on hepatic function and improves hepatic steatohepatitis after 6 months.
    Keshishian A; Zahriya K; Willes EB
    Obes Surg; 2005; 15(10):1418-23. PubMed ID: 16354521
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Obesity: risk factor for steatohepatitis and hepatic fibrosis].
    Poniachik J; Mancilla C; Contreras J; Csendes A; Smok G; Cavada G; Rojas J; Oksenberg D; Burdiles P; Maluenda F; Díaz JC
    Rev Med Chil; 2002 Jul; 130(7):731-6. PubMed ID: 12235896
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The comparison of scoring scales for liver biopsy assessment in morbidly obese patients undergoing bariatric surgery.
    Ziolkowski A; Wylezol M; Kukla M; Zwirska-Korczala K; Berdowska A; Pardela M; Gabriel A
    Obes Surg; 2005 Oct; 15(9):1309-14. PubMed ID: 16259893
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.